Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting Beta2 Agonist BORA
Research payments
$55,217
Through program year 2020, $55,217 in research payments was reported against Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting Beta2 Agonist BORA, across 12 payments.
- Paid by (largest first)
- AstraZeneca Pharmaceuticals LP; AstraZeneca UK Limited
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $131 | 1 |
| 2019 | Research | $55,086 | 11 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Philip Gorelick Chicago, IL Named on 1 payment
- Mila Leong Northfield, NJ Named on 1 payment
- Alan Goldsobel San Jose, CA Named on 1 payment
- Thomas Leblanc Durham, NC Named on 1 payment
- Amy Darter Oklahoma City, OK Named on 1 payment
- Timothy Scialla Charlottesville, VA Named on 1 payment
- Santiago Reyes Oklahoma City, OK Named on 1 payment
- Miriam Garcia Portela Miami, FL Named on 1 payment
- Antonio Blanco Miami, FL Named on 1 payment
- Enrique Davis Bronx, NY Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.